Development and Clinical use of Prasugrel and Ticagrelor

Author(s): Shiraz Ahmad, Robert F. Storey

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 33 , 2012

Become EABM
Become Reviewer


Anti-platelet agents have left an indelible impression in the management of a wide range of pathologies. From the earliest therapeutic agents such as aspirin, to the cutting edge agents still undergoing development, they have the capability to powerfully manipulate platelet biology, a central player in thrombosis. The use of these agents is still subject to a number of important limitations that two newer agents, prasugrel and ticagrelor, aim to address. Both have recently received licensing for use in acute coronary syndromes and promise to improve outcomes for patients. Here, we examine the rationale for the development and clinical integration of antiplatelet agents focusing upon prasugrel and ticagrelor.

Keywords: Platelet inhibitors, P2Y12 receptor, acute coronary syndrome, clopidogrel, prasugrel, ticagrelor

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [5240 - 5260]
Pages: 21
DOI: 10.2174/138161212803251989
Price: $65

Article Metrics

PDF: 24